Findings

What do systematic reviews say?

8 questions · 8 findings · 1 reviews · Kidney and Transplant

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 0 · 0%Low 1 · 12.5%Moderate 3 · 37.5%High 4 · 50%

All symptomatic CMV disease · solid organ transplant recipients

Antiviral prophylaxis leads to lower CMV disease: all symptomatic CMV disease compared with placebo or no treatment (high certainty).

1 finding from 1 review

Antiviral medications for preventing cytomegalovirus disease in solid organ transplant recipients 2024 · Cochrane Headline outcomes only
RR 0.42 [0.34, 0.52]
19 studies · 1981 participants
High

Death associated with CMV disease · solid organ transplant recipients

Antiviral prophylaxis probably leads to lower death due to CMV disease compared with placebo or no treatment (moderate certainty).

1 finding from 1 review

Antiviral medications for preventing cytomegalovirus disease in solid organ transplant recipients 2024 · Cochrane Headline outcomes only
RR 0.26 [0.08, 0.78]
7 studies · 1300 participants
Moderate

All‐cause death · solid organ transplant recipients

Antiviral prophylaxis leads to lower all‐cause death compared with placebo or no treatment (high certainty).

1 finding from 1 review

Antiviral medications for preventing cytomegalovirus disease in solid organ transplant recipients 2024 · Cochrane Headline outcomes only
RR 0.63 [0.43, 0.92]
17 studies · 1838 participants
High

CMV infection · solid organ transplant recipients

Antiviral prophylaxis leads to lower CMV infection compared with placebo or no treatment (high certainty).

1 finding from 1 review

Antiviral medications for preventing cytomegalovirus disease in solid organ transplant recipients 2024 · Cochrane Headline outcomes only
RR 0.61 [0.48, 0.77]
17 studies · 1786 participants
High

Graft loss · solid organ transplant recipients

Antiviral prophylaxis showed no clear difference in graft loss compared with placebo or no treatment (moderate certainty).

1 finding from 1 review

Antiviral medications for preventing cytomegalovirus disease in solid organ transplant recipients 2024 · Cochrane Headline outcomes only
RR 0.74 [0.47, 1.17]
10 studies · 825 participants
Moderate

Acute rejection · solid organ transplant recipients

Antiviral prophylaxis showed no clear difference in acute rejection compared with placebo or no treatment (high certainty).

1 finding from 1 review

Leucopenia · solid organ transplant recipients

Antiviral prophylaxis showed no clear difference in leucopenia compared with placebo or no treatment (moderate certainty).

1 finding from 1 review

Antiviral medications for preventing cytomegalovirus disease in solid organ transplant recipients 2024 · Cochrane Headline outcomes only
RR 1.03 [0.67, 1.59]
4 studies · 1125 participants
Moderate

Kidney dysfunction · solid organ transplant recipients

Antiviral prophylaxis showed no clear difference in kidney dysfunction compared with placebo or no treatment (low certainty).

1 finding from 1 review